Tag Archives: Fierce

Trump Declares War on China and Woke Tech as His 90-Point Action Plan Ignites Fierce Political and Cultural Firestorm

Trump Declares War on China and Woke Tech as His 90-Point Action Plan Ignites Fierce Political and Cultural Firestorm

IN A NUTSHELL 🚀 Trump unveils a comprehensive AI Action Plan, aiming to slash bureaucratic red tape and boost American innovation. 🌐 The plan emphasizes enhancing export capabilities and constructing billion-dollar infrastructure projects to secure U.S. dominance. 🔧 Fast-tracking permits for data centers and launching workforce programs are key strategies to advance the AI agenda. 📈 The administration’s efforts focus …

Read More »

Replimune's shares crater as FDA rejects melanoma drug – Fierce Biotech

Replimune’s shares crater as FDA rejects melanoma drug  Fierce Biotech Replimune skin cancer therapy rejected by FDA, a sign of regulators’ hardened stance  statnews.com Replimune drug rejected by FDA; Omega raises $647M biotech fund  Yahoo Finance Replimmune Plummets Following FDA’s Surprise Rejection of Melanoma Treatment  BioSpace Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment  Barron’s Source link

Read More »

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy – Fierce Biotech

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy  Fierce Biotech We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress  statnews.com Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug  Yahoo Finance Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths  The New York Times …

Read More »

Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion – Fierce Pharma

Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion  Fierce Pharma BMS’ Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial  BioSpace Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes  Endpoints News Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here’s What Investors Are Thinking  Stocktwits Luspatercept Plus …

Read More »